Zoledronic Acid (Zometa, Zomera, Aclasta and Reclast) is effective in reducing skeletal-related events (SRE) such as fractures, spinal cord compression, and surgery or radiation to the bone. To a multiple myeloma patient like me, maintaining bone health is almost the same thing as managing your cancer.
The point made clear in the study linked and excerpted below is that zoledronic acid is toxic and can cause collateral damage in the form of osteonecrosis of the jaw and/or renal dysfunction.
The study discussed below shows that 12 weeks dosing of bisphophonates is just as effective as 4 week dosing yet causes half of the side effects ONJ and renal dysfunction.
To add integrative therapies for bone strengthening such as exercise and magnesium supplementation you will be employing a broad spectrum of therapies to reduce your risk of SRE’s.
For more information about managing your bone health scroll down the page, post a question or comment and I will reply ASAP.
Survivor, Creator, Director PeopleBeatingCancer.
“Patients who have metastatic breast and prostate cancers and multiple myeloma are at risk of skeletal-related events (SRE)…
Zoledronic acid is a bisphosphonate that is FDA approved to treat bone metastases. It reduces SREs when given every 3 to 4 weeks, but an optimal dosing interval has not been determined….
Current interest in bisphosphonates for reducing and delaying SREs focuses on maximizing the benefit and minimizing the risk of these agents…
The study enrolled 1,822 patients, with 911 patients receiving zoledronic acid every 4 weeks, and 911 patients receiving the drug every 12 weeks…
In both study arms, 47% of the patients had breast cancer, 38% had prostate cancer, and 15% had multiple myeloma…”
Comparing the two arms:
- “No significant difference occurred in the proportion of patients with one or more SREs-
- No significant difference occurred in the time to SRE between the two study arms-
- No differences were found in pain scores or performance status over time-
The only difference between the two arms resulted in side effects:
- Rates of osteonecrosis of the jaw were 2% with zoledronic acid at every 4 weeks and 1% at every 12 weeks-
- Renal dysfunction rates were 1.2% (every 4 weeks) and 0.6%, (every 12 weeks)-“
The side effects ONJ and renal dysfunction were twice as severe when bisphophonate were given every 4 weeks compared to given every 12 weeks.